jugs - im reposting what I said in post 2141 which I think gives a good reason why this board isn't spammed like other boards. plus these companies rely on their clinical results to keep the company moving forward. without that, they can't get investors like us or larger ones. I think until we see more clinical results reported from the company, it'll be slow around here.
- i will give you my opinion from two perspectives.
1. emotional perspective - if my analysis of this company is based on what they're trying to accomplish and improve quality of life for debilitating neurodegenerative diseases and stock price with little research, then I think it's a "good buy." they are expanding into other markets/clinics like we've seen from their positive results with autism. my brother-in-law's wife has MS and i'd love to see this company be an option for her in the future (or anyone else for that matter). also, this form of treatment is an alternative for those who want to avoid pharmaceuticals.
2. investing perspective - low stock price, great clinical results, safe method of treatment, only 1 competitor in the market now, debt free, fully funded through their trails. as mentioned in the presentation, their burn rate is approx. 2M/quarter and they raised 16M from warrants. most of their funding is private or through grants in addition to warrants being exercised. if you look at how their warrants are being exercised, tony mentions the details in the presentation. I don't want to attempted the explanation because i'll probably not give the correct detail. it's at the end around minute 19 if you want to fast-forward.
of course the biotech sector has cons, risky, volatile stocks, and gaining FDA approval takes time. the good thing is this company was approved for fast-track so, this will speed things up and I think as long as they continue to have positive results, it's worth paying attention.
minding - I think your approach is good in that you're sitting back but you may want to keep this on the radar this year as we get closer to results in 2016. you might see an uptrend as investors prepare for good news. if you plan on jumping back in before any major announcements this year is probably this best time to buy (in my opinion).
